Search This Blog

Thursday, March 2, 2023

Ticketmaster, PayPal, eBay hassle to report sales even though IRS says they don’t have to

 People are being told they need to provide their Social Security numbers to online platforms and cash transfer app companies for the sales of things like clothes and concert tickets over $600, even though the IRS says they don’t need to.

The prompts from companies like Ebay and Ticketmaster are the result of a change in the tax law that was reneged last-minute by the IRS ahead of the 2023 tax filing season.

The switch is causing a lot of confusion among taxpayers and tax professionals – and even within the IRS itself.

The threshold for reporting business income or personal income from using these apps was supposed to change this year. It was downgraded from sales above $20,000 to sales of above just $600 and was part of a provision passed in the 2021 American Rescue Plan.

That means you’d need to pay a capital gains tax on sales worth more than $600 if you used these apps to receive a payment.

But the IRS decided to delay this rule change from tax season 2023 to tax season 2024, citing “confusion during the … 2023 tax filing season” and the need to “provide more time for taxpayers to prepare and understand the new reporting requirements.”

The IRS said some taxpayers may be receiving 1099-K forms “in error.”

“Some individuals may receive a Form 1099-K for the sale of personal items or in situations where they received a Form 1099-K in error (i.e. for transactions between friends and family, or expense sharing),” the agency said in a statement.

Asking for Social Security number after sale

That confusion is proving to be a real frustration for some sellers and is leading companies to ask for sensitive information from their customers in an effort to be compliant with the law.

“Ebay prompted me to enter my Social [Security number] after I ‘sold’ over $600 in items last month. I’m assuming it’s for next year,” a person by the name of Allison Chao said Wednesday in an online forum discussing the changes in IRS rules.

“The word ‘sold’ is in quotes because the transactions were actually charged sales tax by Ebay which counted towards the $600 (I didn’t receive any of that tax personally),” Chao wrote. “Really upset me!”

That kind of confusion has been felt elsewhere, even as expectations for a smoother tax season have been bolstered by new funding for the IRS.

“Ticketmaster made me enter SS info after I resold a single concert for less than I paid for it,” a person identified as Stacey Silber Shea said in the same online forum.

Making things even more confusing, if taxpayers are selling personal items at a loss, they should be reporting those on one kind of form, and if they’re selling them at a gain, they should be reporting them on another.

Losses go on a 1099-K and gains go on a 1040, the IRS says.

Ebay confirmed to The Hill that it has “taken steps to comply with the new IRS 1099-K reporting requirements, including collecting [S]ocial [S]ecurity numbers from customers when they pass the $600 threshold.”

It’s on sellers to stay within tax laws

On top of that, as online sales companies pester customers in order to stay compliant, customers are being told by the IRS that it’s their job to sort things out with the companies if they feel they’re getting prompts in error.This is a common problem in the case of cash transfer apps, which are termed “third-party settlement organizations” by the IRS, because it’s easy to confuse personal purchases and money transfers with sales that generate personal income, which is taxable under the law.

“Third-party settlement organizations and users repeatedly asked the IRS to provide useful guidance,” the National Taxpayer Advocate (NTA), which is an office within the IRS, said in a statement summarizing all the confusion for taxpayers last month.

“And the IRS’s response was largely to tell taxpayers that if a Form 1099-K is erroneous, they needed to go back to the third-party provider and convince the provider to issue a corrected Form 1099-K,” it reads. “Given the anticipated volume of Forms 1099-K – which likely is in the tens of millions – that was not a realistic solution.”

These demands are adding to the already considerable stress of taxpayers who are simply trying to stay within the bounds of the law.

“Last year, Paypal stopped allowing personal payments on accounts that are marked as business so I started getting hit with those 3-percent fees, and I thought, you know, whatever,” Lev Epshtyn, a tech worker in New York, said in an interview.

“But then toward the end of the year, I realized they’re about to send me one of those forms, the 1099, for all that money that my friends were paying me for restaurant expenses and things like that,” he said.

“So I actually had to call them back and get them to declassify my account from business back to personal,” he said. “I was scrambling.”

Gig workers in particular pressured

Professional tax preparers say they can see the stress the rule-switching is causing in their customers.

“Online [sellers] and drivers” are the people most affected among the clientele of Umar Farooq, one of the IRS’s enrolled agents, who are tax preparers officially recognized by the IRS.

“Amazon sellers deal with this. And then the most affected are the Uber drivers, the Lyft drivers, because [they get paid through] the third party,” Farooq said.

“They were just confused and they didn’t know if they were going to be issued a 1099 or no,” he said.

Other professionals dealing with the issues have seen similar headaches.

“There was concern. Should people be getting a 1099 for the personal [sales]? That’s what most of the people are asking,” Abdul Hannan, a tax preparer in Brooklyn told The Hill. “With Venmo and Cashapp, they don’t know if it’s business or if it’s personal, so people are confused.”

The IRS describes the reporting changes for next year as “hugely important” because they could affect tax compliance in a big way.

“However, the IRS noted it must be managed carefully to help ensure that 1099-Ks are only issued to taxpayers who should receive them,” the IRS said in a statement in January.

“In addition, it’s important that taxpayers understand what to do as a result of this reporting, and tax preparers and software providers have the information they need to assist taxpayers,” the statement reads.

The Hill reached out to Amazon, Venmo, Cash App, Ticketmaster and PayPal for comment.

https://thehill.com/homenews/3879806-ticketmaster-paypal-ebay-are-hassling-customers-to-report-sales-even-though-the-irs-says-they-dont-have-to/

Avenue to Develop and Commercialize Treatment of Spinal and Bulbar Muscular Atrophy

 AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapy

 Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. (“AnnJi”), a Taiwanese clinical-stage drug company, for AJ201, a first-in-class clinical asset currently in a Phase 1b/2a study in the U.S. for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease.

https://finance.yahoo.com/news/avenue-therapeutics-enters-transformational-license-130000630.html

GSK spinoff Haleon has no deals on immediate horizon

 Consumer healthcare group Haleon's Chief Executive Brian McNamara said on Thursday he does not expect to announce any acquisitions or divestments imminently, amid analyst concerns its 2023 cost forecasts could hit consensus profit estimates.

McNamara told Reuters that both types of transactions were on the cards, but added "there's certainly nothing imminent that is out there that I would talk about today".

Haleon, carved out of British drugmaker GSK in July in the biggest listing in Europe for more than a decade, is the world's biggest standalone consumer health business selling non-prescription drugs, vitamins and oral care products.

There is widespread talk of consolidation in the highly fragmented sector, with big pharma majors offloading their consumer health businesses to focus on their high-risk, high-reward field of prescription medicines.

"The consumer healthcare sector is evolving rapidly, and Haleon needs to be an acquiror rather than a target," Lucy Coutts, investment director at wealth management firm JM Finn, which holds Haleon shares, told Reuters.

With very significant cost savings associated with M&A, given the top five companies hold 16% of the global consumer health business, consolidation seems highly likely longer term, Barclays analyst Iain Simpson told Reuters this week.

SHARE DROP

Haleon has navigated a highly volatile macro-economic environment in 2022 - with double digit inflation on things like input costs, McNamara said, adding that he expects inflation to continue to rise more in the mid-single digit range this year.

Rivals with consumer health operations, such as Bayer and Reckitt, have charged higher prices to partly offset broader falls in sales volumes.

McNamara said Haleon expects its 4% to 6% growth in 2023 will be fuelled by price increases more than higher volumes.

Players in the consumer health field, like other sectors, have been contending with sharp cost increases across the business, including raw materials, transport and energy linked to the war in Ukraine and lingering COVID-19 disruptions.

Merck KGaA Sees Challenging 2023 After Rises in 2022 Earnings, Sales

 Germany's Merck KGaA said Thursday that it expects a challenging 2023, with adjusted earnings forecast to be stable or decline slightly and a hit from foreign-exchange rates, as it reported a rise in after-tax profit and net sales for last year.

The life-sciences and electronics company said after-tax profit for 2022 was 3.34 billion euros ($3.56 billion) compared with EUR3.07 billion in 2021. Net sales rose 13% to EUR22.23 billion, with life-science sales up 15% and sales up 11% in both healthcare and electronics.

Merck said Ebitda pre--a closely-watched company metric which measures earnings before interest, taxes, depreciation and amortization before one-time items--grew 12% to EUR6.85 billion.

Analysts expected 2022 Ebitda pre to come in at EUR6.92 billion on net sales of EUR22.25 billion, according to consensus estimates provided by the company.

Merck said it expects 2023 to be a challenging year due to a slowdown in the semiconductor market, falling Covid-19-related demand, high inflation and negative foreign-exchange effects. The company said it expects further organic growth in net sales, but that organic Ebitda pre will fall slightly or be stable due to cost inflation.

https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-KGaA-Sees-Challenging-2023-After-Rises-in-2022-Earnings-Sales-43131808/

MyMD: 'DEA Says Supera-CBD is not a Controlled Substance or Listed Chemical'

 MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific review and determined that investigational cannabinoid Supera-CBD™ is not currently considered a controlled substance or listed chemical. The scientific review of the chemical structure of Supera-CBD was conducted in accordance with the Controlled Substances Act (CSA) and its governing regulations.

"Currently, all FDA-approved cannabinoid products are considered controlled substances, with the exception of Epidiolex, and although plant-derived cannabidiol (CBD) is unscheduled, its use by military and federal civilian employees currently is prohibited without a valid prescription. This decision by the DEA is tremendous news for Supera-CBD and we are very pleased that our product candidate will not require DEA scheduling during development," said Christopher Chapman, MD, President, Director, and Chief Medical Officer at MyMD Pharmaceuticals. "We look forward to studying Supera-CBD’s potential to improve upon the benefits of CBD while retaining its safety and tolerability without intoxicating effects."

"It is a tremendous benefit to be able to conduct drug development without the burden of dealing with a scheduled product," said Dr. Jack Henningfield, Vice President, Research, Health Policy, and Abuse Liability at Pinney Associates, Inc. "We look forward to continuing our support of MyMD Pharmaceuticals as Supera-CBD advances through development."

Supera-CBD™ is a synthetic, non-toxic cannabidiol (CBD) analog that is an 8000-times more potent CB2 agonist than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown in preclinical studies to have anti-inflammatory effects. Supera-CBD is a unique synthetic analog of CBD whose structure has been modified to be CB2-receptor selective. Studies to investigate Supera-CBD’s binding and affinity to CB1 and CB2 receptors show that the compound had very low affinity to CB1 and had a four-fold increase in binding to the CB2 receptor in comparison to CBD. Supera-CBD has completed genotoxicity studies and the company has initiated preclinical pain studies in partnership with Johns Hopkins Medicine.

Pfizer Confirms It Ended COVID-19 Vaccine Pregnancy Trial Early

 by Zachary Steiber via The Epoch Times (emphasis ours),

Pfizer has confirmed it stopped its clinical trial analyzing COVID-19 vaccine safety and efficacy in pregnant women early.

The company said that enrollment in the study stopped in the fourth quarter of 2021 after health experts, including the U.S. Advisory Committee on Immunization Practices, began recommending the Pfizer-BioNTech vaccine for pregnant women.

With the declining enrollment, the study had insufficient sample size to assess the primary immunogenicity objective and continuation of this placebo controlled study could no longer be justified due to global recommendations,” Pfizer told journalist Maryanne Demasi.

The U.S. Food and Drug Administration and European Medicines Agency both agreed to the proposal to halt the study, according to Pfizer. The regulatory agencies did not respond to requests for comment.

An internal email, disclosed in a court case, previously indicated Pfizer had stopped enrollment early.

“The study enrolment was stopped with incomplete numbers because recruitment was slow and it became unreasonable/inappropriate to randomise pregnant women to placebo given the amount of observational evidence that the vaccine is safe and effective, coupled with increasing number of technical committees supporting immunization of pregnant women,” Jelena Vojicic, vaccines medical lead at Pfizer Canada, wrote in the 2022 email.

The randomized, placebo-controlled study in question was launched in early 2021 after pregnant women were excluded from the phase three trial that led to the authorization of the vaccine in the United States and a number of other countries.

Pfizer and BioNTech said they expected to enroll some 4,000 pregnant women but actually enrolled just 349, according to the trial record. Some of the participants were to receive a vaccine while others would receive a placebo, according to the original protocol. Women were expected to be studied for seven to 10 months.

The trial was listed as completed on Aug. 23, 2022, but no results have been released yet.

Pfizer told Demasi that it still does not have “a complete data set” from the study and did not say when it expected to receive it. Pfizer said it and BioNTech plan to complete an analysis of the trial “and seek publication or presentation as is our standard practice.”

Pfizer officials told CDC advisers in September 2022 that the study was completed.

“We will be generating data from that study despite the difficulties in enrollment … due to the wide recommendations for pregnant women to be vaccinated, but we will generate those data for sure,” Nicholas Kitchen, a senior Pfizer vaccine official, told the panel.

Pfizer did not respond to requests for more information.

https://www.zerohedge.com/covid-19/pfizer-confirms-it-ended-covid-19-vaccine-pregnancy-trial-early

House Republicans Accuse Biden White House Of Creating 'Authoritarian-Style' Digital Dollar

 by Andrew Moran via The Epoch Times (emphasis ours),

President Joe Biden and his administration are attempting to develop an “authoritarian-style” and “surveillance-style” digital U.S. dollar through executive orders, warned House Majority Whip Tom Emmer (R-Minn.) on Tuesday.

The four-term congressman recently introduced the CBDC Anti-Surveillance State Act to prohibit “unelected bureaucrats” in Washington from issuing a central bank digital currency that critics argue could diminish Americans’ financial privacy rights.

The bill, which has several Republican co-sponsors, including Rep. Andy Biggs (R-Ariz.) and Rep. Young Kim (R-Calif.), would also ensure that the Federal Reserve is held accountable in its research and development of a digital dollar.

The consequences, if we get it wrong, are far too serious,” Emmer said at a news conference. “The Biden administration is currently itching to create a digital authoritarian-style, surveillance-style digital dollar through an executive order.”

The bill, Emmer says, would restrict the central bank from issuing a CBDC or using a CBDC to implement monetary policy and control the national economy.

He added that efforts to digitize the U.S. dollar need to be transparent and protect Americans’ right to financial privacy. Developing a digital version of the greenback must enhance financial inclusion, ensure transactions are efficient, and refrain from threatening Americans’ privacy or sovereignty.

U.S. Rep.-elect Rep. Tom Emmer (R-Minn.) talks to reporters as he leaves his office at the U.S. Capitol Building in Washington on Jan. 05, 2023. (Nathan Howard/Getty Images)

“We need these common-sense guardrails to prevent unelected bureaucrats here in Washington from sacrificing Americans’ right to financial privacy,” he said. “We do not want to emulate the CCP. We should not be taking our direction from the Communist Party of China.

In March 2022, President Biden signed an executive order that requested the Federal Reserve to continue its ongoing CBDC research, experimentation, and evaluation to determine the benefits and risks of a digital dollar.

Bullish on a CBDC?

Over the last couple of years, the Fed and the Treasury Department have published several CBDC-related reports.

Speaking at a panel discussion hosted by the Bank for International Settlements (BIS) in March 2022, Fed Chair Jerome Powell outlined his four qualifications to support a digital dollar: privacy, verifiable, intermediated, and widely accepted as a means of payment.

https://www.zerohedge.com/economics/house-republicans-accuse-biden-white-house-creating-authoritarian-style-digital-dollar